Healthcare entity
Every one of those 1 sits in a single category, acquisition. PolyPeptide Group AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Samsung Biologics, all published on July 20, 2026.
Last mentioned: Jul 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, acquisition. PolyPeptide Group AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Samsung Biologics, all published on July 20, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Samsung Biologics. Shared-story counts are live from our verified record — not editorial picks.
Samsung Biologics' tender offer for PolyPeptide brings peptide API manufacturing in-house, reinforcing supply chain resilience for hormone therapies, antibiotics, and emerging biotherapeutics. The deal expands capacity across the U.S., Europe, and India, potentially reducing the risk of shortages that have plagued certain peptide drugs.
Samsung Biologics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
